華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022

On 13 October 2022, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2022.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) ("**Dong-E-E-Jiao**") is a company incorporated in the People's Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 13 October 2022, Dong-E-E-Jiao released its results estimate for the nine months ended 30 September 2022. In which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the nine months ended 30 September 2022 would range from RMB460.00 million to RMB560.00 million, representing an increase between 53% and 86% as compared to the net profit of RMB301.2719 million for the same period last year (the "**Dong-E-E-Jiao Results Estimate**").

The main reasons for the change in results are set forth as follows:

Dong-E-E-Jiao continued to deepen its strategic planning for the "14th Five Year Period" and invigorated endogenous strengths by innovating its customer operation model through digitalisation based on the principle of "reshaping values, businesses, organisation and ethos"; strong efforts were made to drive the development of Dong-E-E-Jiao as a first-rate national brand name for nourishment products in a comprehensive implementation of brand awareness and brand renewal to enhance its brand power; and it was determined to enhance its core businesses and accelerate product innovation to reinforce its core competitiveness and achieve positive growth in results.

Dong-E-E-Jiao will actively integrate itself into the national big health development strategy, aiming to achieve qualitative development as it endeavours to forge a business model underpinned by pharmaceutical and consumer health products as dual business drivers to stabilise its leading position in the blood and internal strength nourishment sector; with accurate understanding of consumer demands based on customer operation, specialised services and standardised experiences will be offered; innovative technologies will be developed on a market-oriented basis to enhance the commercialisation of research in an ongoing effort to build a prestigious R&D centre for TCM gelatin products; efforts will also be made to stimulate organisational vigour and enhance organisational efficiency through organisational reform to build a foundation for its positive growth.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of the financial data, those to be disclosed in the quarterly report for the nine months ended 30 September 2022 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 14 October 2022

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Weng Jingwen as executive Directors, Mr. Lin Guolong, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.